Wall Street analysts predict that Edwards Lifesciences Corp (NYSE:EW) will post earnings per share of $1.03 for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for Edwards Lifesciences’ earnings. The highest EPS estimate is $1.08 and the lowest is $0.99. Edwards Lifesciences posted earnings of $0.84 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 22.6%. The firm is expected to announce its next quarterly earnings report on Tuesday, October 23rd.

On average, analysts expect that Edwards Lifesciences will report full year earnings of $4.65 per share for the current financial year, with EPS estimates ranging from $4.58 to $4.71. For the next fiscal year, analysts expect that the business will report earnings of $5.21 per share, with EPS estimates ranging from $4.91 to $5.50. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.11. The company had revenue of $972.00 million during the quarter, compared to analysts’ expectations of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. Edwards Lifesciences’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.08 earnings per share.

A number of research analysts recently commented on EW shares. BMO Capital Markets boosted their price target on Edwards Lifesciences to $162.00 and gave the company an “outperform” rating in a research note on Tuesday, July 10th. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Tuesday, June 12th. Northland Securities downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 25th. Royal Bank of Canada boosted their target price on Edwards Lifesciences to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 23rd. Finally, JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and sixteen have assigned a buy rating to the company. Edwards Lifesciences has an average rating of “Buy” and an average price target of $152.95.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction that occurred on Thursday, May 17th. The stock was sold at an average price of $135.88, for a total value of $4,470,452.00. Following the sale, the chief executive officer now directly owns 112,731 shares in the company, valued at $15,317,888.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Larry L. Wood sold 6,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $137.26, for a total value of $864,738.00. The disclosure for this sale can be found here. Insiders sold 163,115 shares of company stock worth $23,153,748 over the last quarter. 1.84% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. HighPoint Advisor Group LLC grew its stake in shares of Edwards Lifesciences by 38.0% during the 1st quarter. HighPoint Advisor Group LLC now owns 2,897 shares of the medical research company’s stock worth $414,000 after acquiring an additional 798 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its holdings in shares of Edwards Lifesciences by 269.6% during the 1st quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 37,374 shares of the medical research company’s stock valued at $5,090,000 after acquiring an additional 27,261 shares in the last quarter. Global Financial Private Capital LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter valued at $624,000. Teacher Retirement System of Texas lifted its holdings in shares of Edwards Lifesciences by 9.1% during the 1st quarter. Teacher Retirement System of Texas now owns 98,385 shares of the medical research company’s stock valued at $13,727,000 after acquiring an additional 8,195 shares in the last quarter. Finally, Xact Kapitalforvaltning AB increased its stake in Edwards Lifesciences by 2.6% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 42,018 shares of the medical research company’s stock worth $6,117,000 after buying an additional 1,084 shares during the period. Institutional investors and hedge funds own 81.68% of the company’s stock.

Edwards Lifesciences traded down $3.13, reaching $139.62, during midday trading on Wednesday, Marketbeat.com reports. The company had a trading volume of 23,606 shares, compared to its average volume of 1,329,726. The company has a market cap of $30.40 billion, a PE ratio of 36.85, a price-to-earnings-growth ratio of 2.11 and a beta of 0.60. Edwards Lifesciences has a 1-year low of $100.20 and a 1-year high of $156.87. The company has a quick ratio of 1.47, a current ratio of 1.86 and a debt-to-equity ratio of 0.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Read More: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.